Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings.

Ekouevi DK, Inwoley A, Tonwe-Gold B, Danel C, Becquet R, Viho I, Rouet F, Dabis F, Anglaret X, Leroy V.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1469-74.


Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.

Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.

AIDS. 2008 Sep 12;22(14):1815-20. doi: 10.1097/QAD.0b013e32830b8ab9.


Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.


Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.

Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team..

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7.


Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.

Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T.

AIDS. 2003 Jul;17 Suppl 3:S5-15.


Immune status and uptake of antiretroviral interventions to prevent mother-to-child transmission of HIV-1 in Africa.

Ekouevi DK, Rouet F, Becquet R, Inwoley A, Viho I, Tonwe-Gold B, Bequet L, Dabis F, Leroy V; ANRS 1201/1202 Ditrame Plus Study Group..

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):755-7.


Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.


Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine.

Ekpini RA, Nkengasong JN, Sibailly T, Maurice C, Adjé C, Monga BB, Roels TH, Greenberg AE, Wiktor SZ.

AIDS. 2002 Mar 8;16(4):625-30.


Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Côte d'Ivoire: a 7-year cohort study.

Loko MA, Toure S, Dakoury-Dogbo N, Gabillard D, Leroy V, Anglaret X.

AIDS. 2005 Mar 4;19(4):443-5.


Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire.

Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X.

Antivir Ther. 2005;10(5):615-24.


Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.

Kowalska A, Niemiec T, El Midaoui A, Burkacka E.

Med Wieku Rozwoj. 2003 Oct-Dec;7(4 Pt 1):459-68.


Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil.

Pilotto JH, Velasque LS, Friedman RK, Moreira RI, Veloso VG, Grinsztejn B, Morgado MG, Watts DH, Currier JS, Hoffman RM.

Antivir Ther. 2011;16(3):349-56. doi: 10.3851/IMP1779.


The relationship of pregnancy to the use of highly active antiretroviral therapy.

Minkoff H, Ahdieh L, Watts H, Greenblatt RM, Schmidt J, Schneider M, Stek A.

Am J Obstet Gynecol. 2001 May;184(6):1221-7.


Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.

Ekouevi DK, Coffie PA, Chaix ML, Tonwe-Gold B, Amani-Bosse C, Leroy V, Abrams EJ, Dabis F.

J Int AIDS Soc. 2010 Aug 2;13:28. doi: 10.1186/1758-2652-13-28.


Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.

Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L.

Trop Med Int Health. 2010 Jul;15(7):825-32. doi: 10.1111/j.1365-3156.2010.02538.x.


Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.

Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bédikou G, Abrams EJ, Dabis F, Ekouevi DK.

BMC Infect Dis. 2010 Jun 24;10:188. doi: 10.1186/1471-2334-10-188.


Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226.


CD4+ T-lymphocytes natural decrease in HAART-naïve HIV-infected adults in Abidjan.

Duvignac J, Anglaret X, Kpozehouen A, Inwoley A, Seyler C, Toure S, Gourvellec G, Messou E, Gabillard D, Thiébaut R.

HIV Clin Trials. 2008 Jan-Feb;9(1):26-35. doi: 10.1310/hct0901-26.


The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.

Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, Gabillard D, Seyler C, Freedberg KA, Anglaret X.

Antivir Ther. 2007;12(4):543-51.

Supplemental Content

Support Center